By Katherine Hamilton
Shares of Apogee Therapeutics advanced after sharing positive interim results that push forward more trials of inflammatory and immunology treatments.
The stock rose 6% to $33.37 on Monday. Shares have lost about a quarter of their value in 2025.
The biotechnology company reported positive interim results for the Phase 1 of APG990, a product that, when combined with another product called APG777, could treat several inflammatory and immunology diseases including asthma and atopic dermatitis.
Data from its Phase 1 trial for APG777 showed consistent safety results and supports the ongoing Phase 2 clinical trial, Apogee said.
Based on the data, Apogee plans to start its first combination trial of APG777 and APG990 used together, in 2025.
Apogee said it has enough existing cash, cash equivalents and securities to fund operations into the first quarter of 2028.
It had a loss of $182.1 million in 2024, compared with a loss of $84 million the prior year. The company said it has been spending more on research and development to start new trials, and increasing its headcount to expand operations, all of which has contributed to higher expenses and a wider loss.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 03, 2025 12:31 ET (17:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。